Progranulin (PGRN) expression in ALS: an immunohistochemical study
- PMID: 18848708
- DOI: 10.1016/j.jns.2008.08.024
Progranulin (PGRN) expression in ALS: an immunohistochemical study
Abstract
Mutations in the gene progranulin (PGRN) were recently identified as the cause of some forms of frontotemporal dementia with ubiquitin-positive intraneuronal inclusion pathology (FTLD-U). The DNA-binding protein, TDP-43, was determined to be a component of these ubiquitinated inclusions in FTLD-U and amyotrophic lateral sclerosis (ALS) with dementia (ALS-D). These findings raise many interesting questions as to the shared pathology and possible common pathologic process between ALS and FTLD-U. This study examines the immunoexpression of PGRN in ALS patients using immunohistochemical analysis of post-mortem tissue. Available brain and spinal cord sections of eight ALS patients, including one case with severe dementia, and eighteen control-aged brains were stained with anti-PGRN antibodies. We found increased staining for PGRN in motor tracts with vacuolar degeneration and glial cells in ALS sample spinal cord and brainstem sections compared to controls. Variable upper motor neuron staining and reactive glia were seen in ALS motor cortex samples. Frontal lobe and hippocampal sections showed no consistent differences from control tissues with the exception of the ALS-dementia case, which showed PGRN immunoexpression in non-motor cortical areas. These results describe a pattern of increased PGRN expression in areas of active degeneration in ALS. The meaning of this association is unclear, but may indicate a potential role for PGRN in the variable expression of motor and cognitive deficits in the ALS-FTD spectrum.
Similar articles
-
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations.J Neuropathol Exp Neurol. 2007 Feb;66(2):142-51. doi: 10.1097/nen.0b013e31803020cf. J Neuropathol Exp Neurol. 2007. PMID: 17278999
-
Progranulin genetic variability contributes to amyotrophic lateral sclerosis.Neurology. 2008 Jul 22;71(4):253-9. doi: 10.1212/01.wnl.0000289191.54852.75. Epub 2008 Jan 9. Neurology. 2008. PMID: 18184915
-
Alzheimer disease pathology in amyotrophic lateral sclerosis.Acta Neuropathol. 2004 Jun;107(6):515-22. doi: 10.1007/s00401-004-0843-1. Epub 2004 Mar 16. Acta Neuropathol. 2004. PMID: 15024584
-
The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis.Amyotroph Lateral Scler. 2008 Dec;9(6):323-38. doi: 10.1080/17482960802372371. Amyotroph Lateral Scler. 2008. PMID: 18752088 Review.
-
Loss of progranulin function in frontotemporal lobar degeneration.Trends Genet. 2008 Apr;24(4):186-94. doi: 10.1016/j.tig.2008.01.004. Epub 2008 Mar 6. Trends Genet. 2008. PMID: 18328591 Review.
Cited by
-
RNA processing pathways in amyotrophic lateral sclerosis.Neurogenetics. 2010 Jul;11(3):275-90. doi: 10.1007/s10048-010-0239-4. Epub 2010 Mar 27. Neurogenetics. 2010. PMID: 20349096 Review.
-
Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degenerations: Similarities in Genetic Background.Diagnostics (Basel). 2021 Mar 13;11(3):509. doi: 10.3390/diagnostics11030509. Diagnostics (Basel). 2021. PMID: 33805659 Free PMC article. Review.
-
TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.J Biol Chem. 2012 May 4;287(19):15635-47. doi: 10.1074/jbc.M111.333450. Epub 2012 Mar 16. J Biol Chem. 2012. PMID: 22427648 Free PMC article.
-
Progranulin: an emerging target for FTLD therapies.Brain Res. 2012 Jun 26;1462:118-28. doi: 10.1016/j.brainres.2012.01.047. Epub 2012 Jan 28. Brain Res. 2012. PMID: 22338605 Free PMC article. Review.
-
FTD and ALS: a tale of two diseases.Curr Alzheimer Res. 2011 May;8(3):273-94. doi: 10.2174/156720511795563700. Curr Alzheimer Res. 2011. PMID: 21222600 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous